Persistent fibrosis in the liver of choline-deficient and iron-supplemented l-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation

Toxicology and Applied Pharmacology

Volumn 268, Issue 3, 2013, Pages 264-277

  Takeuchi Yorimoto, Ayano ^a   Noto, Takahisa ^a   Yamada, Atsushi ^a   Miyamae, Yoichi ^a   Oishi, Yuji ^a   Matsumoto, Masahiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Fibrosis; Hypoxia; NASH; Oxidative stress

Indexed keywords

3 NITROTYROSINE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; AMINO ACID; ASPARTATE AMINOTRANSFERASE; CATALASE; CD34 ANTIGEN; CHOLINE; CYTOCHROME P450 2E1; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; VITAMIN SUPPLEMENTATION; WESTERN BLOTTING;

AMINO ACIDS; ANIMALS; CHOLINE; CHOLINE DEFICIENCY; DIETARY SUPPLEMENTS; FATTY LIVER; IRON; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR;

EID: 84875301048     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.01.027     Document Type: Article

References (80)

1. Abdel-Aziz G., Lebeau G., Rescan P.Y., Clement B., Rissel M., Deugnier Y., Campion J.P., Guillouzo A. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. Am. J. Pathol. 1990, 137:1333-1342.
2. Angermuller S., Islinger M., Volkl A. Peroxisomes and reactive oxygen species, a lasting challenge. Histochem. Cell Biol. 2009, 131:459-463.
3. Arteel G.E., Thurman R.G., Yates J.M., Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 1995, 72:889-895.
4. Arteel G.E., Thurman R.G., Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur. J. Biochem. 1998, 253:743-750.
5. Baldwin S.J., Bramhall J.L., Ashby C.A., Yue L., Murdock P.R., Hood S.R., Ayrton A.D., Clarke S.E. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab. Dispos. 2006, 34:1063-1069.
6. Baskol G., Baskol M., Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin. Biochem. 2007, 40:776-780.
7. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
8. Behari J., Yeh T.H., Krauland L., Otruba W., Cieply B., Hauth B., Apte U., Wu T., Evans R., Monga S.P. Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am. J. Pathol. 2010, 176:744-753.
9. Berthiaume F., Barbe L., Mokuno Y., MacDonald A.D., Jindal R., Yarmush M.L. Steatosis reversibly increases hepatocyte sensitivity to hypoxia-reoxygenation injury. J. Surg. Res. 2009, 152:54-60.
10. Bomzon A., Ljubuncic P. Oxidative stress and vascular smooth muscle cell function in liver disease. Pharmacol. Ther. 2001, 89:295-308.
11. Brown B.N., Valentin J.E., Stewart-Akers A.M., McCabe G.P., Badylak S.F. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 2009, 30:1482-1491.
12. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94:2467-2474.
13. Buchman A.L., Dubin M.D., Moukarzel A.A., Jenden D.J., Roch M., Rice K.M., Gornbein J., Ament M.E. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995, 22:1399-1403.
14. Cassiman D., van Pelt J., De Vos R., Van Lommel F., Desmet V., Yap S.H., Roskams T. Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am. J. Pathol. 1999, 155:1831-1839.
15. Cassiman D., Libbrecht L., Desmet V., Denef C., Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol. 2002, 36:200-209.
16. Cobb L.M., Nolan J., Butler S.A. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. Br. J. Cancer 1990, 62:915-918.
17. Copple B.L., Bustamante J.J., Welch T.P., Kim N.D., Moon J.O. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes. Liver Int. 2009, 29:1010-1021.
18. Corbin K.D., Zeisel S.H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr. Opin. Gastroenterol. 2012, 28:159-165.
19. Coulon S., Heindryckx F., Geerts A., Van Steenkiste C., Colle I., Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011, 31:146-162.
20. de Wit N.J., Afman L.A., Mensink M., Muller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. 2012, 57:1370-1373.
21. DeLeve L.D. Hepatic microvasculature in liver injury. Semin. Liver Dis. 2007, 27:390-400.
22. Denda A., Kitayama W., Murata A., Kishida H., Sasaki Y., Kusuoka O., Tsujiuchi T., Tsutsumi M., Nakae D., Takagi H., Konishi Y. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis 2002, 23:245-256.
23. Friedman S.L., Bansal M.B. Reversal of hepatic fibrosis-fact or fantasy?. Hepatology 2006, 43:S82-S88.
24. Fujita K., Nozaki Y., Yoneda M., Wada K., Takahashi H., Kirikoshi H., Inamori M., Saito S., Iwasaki T., Terauchi Y., Maeyama S., Nakajima A. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcohol. Clin. Exp. Res. 2010, 34(Suppl. 1):S18-S24.
25. Ghafar M.A., Anastasiadis A.G., Olsson L.E., Chichester P., Kaplan S.A., Buttyan R., Levin R.M. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab. Invest. 2002, 82:903-909.
26. Goodman Z.D., Becker R.L., Pockros P.J., Afdhal N.H. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007, 45:886-894.
27. Halliwell B., Zhao K., Whiteman M. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good: a personal view of recent controversies. Free Radic. Res. 1999, 31:651-669.
28. Hassan Z.K., Elobeid M.A., Virk P., Omer S.A., ElAmin M., Daghestani M.H., AlOlayan E.M. Bisphenol A induces hepatotoxicity through oxidative stress in rat model. Oxid. Med. Cell. Longev. 2012, 2012:194829.
29. Hautekeete M.L., Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 1997, 430:195-207.
30. Hensley K., Kotake Y., Sang H., Pye Q.N., Wallis G.L., Kolker L.M., Tabatabaie T., Stewart C.A., Konishi Y., Nakae D., Floyd R.A. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 2000, 21:983-989.
31. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
32. Hubscher S.G. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465.
33. Iredale J.P., Benyon R.C., Pickering J., McCullen M., Northrop M., Pawley S., Hovell C., Arthur M.J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Investig. 1998, 102:538-549.
34. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R.N., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995, 22:696-699.
35. Issa R., Zhou X., Constandinou C.M., Fallowfield J., Millward-Sadler H., Gaca M.D., Sands E., Suliman I., Trim N., Knorr A., Arthur M.J., Benyon R.C., Iredale J.P. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
36. Ito A., Nomura S., Hirota S., Suda J., Suda T., Kitamura Y. Enhanced expression of CD34 messenger RNA by developing endothelial cells of mice. Lab. Invest. 1995, 72:532-538.
37. Jang Y.S., Lee M.H., Lee S.H., Bae K. Cu/Zn superoxide dismutase is differentially regulated in period gene-mutant mice. Biochem. Biophys. Res. Commun. 2011, 409:22-27.
38. Jimenez-Lopez J.M., Cederbaum A.I. CYP2E1-dependent oxidative stress and toxicity: role in ethanol-induced liver injury. Expert Opin. Drug Metab. Toxicol. 2005, 1:671-685.
39. Kajdaniuk D., Marek B., Foltyn W., Kos-Kudla B. Vascular endothelial growth factor (VEGF)-part 1: in physiology and pathophysiology. Endokrynol. Pol. 2011, 62:444-455.
40. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., Igura T., Maeda N., Kihara S., Funahashi T., Matsuzawa Y., Shimomura I., Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 2007, 47:556-564.
41. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
42. Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., Ozercan I.H., Sahin K., Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008, 31:91-98.
43. Kohli R., Kirby M., Xanthakos S.A., Softic S., Feldstein A.E., Saxena V., Tang P.H., Miles L., Miles M.V., Balistreri W.F., Woods S.C., Seeley R.J. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934-944.
44. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:195-206.
45. Li J., Billiar T.R. Nitric oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am. J. Physiol. 1999, 276:G1069-G1073.
46. Lieber C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 1997, 77:517-544.
47. Lieber C.S. CYP2E1: from ASH to NASH. Hepatol. Res. 2004, 28:1-11.
48. Maeda T., Adachi E., Kajiyama K., Takenaka K., Honda H., Sugimachi K., Tsuneyoshi M. CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings. J. Gastroenterol. Hepatol. 1995, 10:650-654.
49. Mas E., Danjoux M., Garcia V., Carpentier S., Segui B., Levade T. The pro-inflammatory action of tumour necrosis factor-alpha in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Dig. Liver Dis. 2013, 45:147-154.
50. Matsunami T., Sato Y., Ariga S., Sato T., Kashimura H., Hasegawa Y., Yukawa M. Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Int. J. Clin. Exp. Pathol. 2010, 3:472-481.
51. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
52. Moon J.O., Welch T.P., Gonzalez F.J., Copple B.L. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G582-G592.
53. Mu Y.P., Ogawa T., Kawada N. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Lab. Invest. 2010, 90:245-256.
54. Muriel P. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem. Pharmacol. 1998, 56:773-779.
55. Naito M., Hasegawa G., Ebe Y., Yamamoto T. Differentiation and function of Kupffer cells. Med. Electron Microsc. 2004, 37:16-28.
56. Nakae D. Endogenous liver carcinogenesis in the rat. Pathol. Int. 1999, 49:1028-1042.
57. Nakae D., Yoshiji H., Maruyama H., Kinugasa T., Denda A., Konishi Y. Production of both 8-hydroxydeoxyguanosine in liver DNA and gamma-glutamyltransferase-positive hepatocellular lesions in rats given a choline-deficient, L-amino acid-defined diet. Jpn. J. Cancer Res. 1990, 81:1081-1084.
58. Novo E., Povero D., Busletta C., Paternostro C., di Bonzo L.V., Cannito S., Compagnone A., Bandino A., Marra F., Colombatto S., David E., Pinzani M., Parola M. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J. Pathol. 2012, 226:588-597.
59. Oldreive C., Rice-Evans C. The mechanisms for nitration and nitrotyrosine formation in vitro and in vivo: impact of diet. Free Radic. Res. 2001, 35:215-231.
60. Omori N., Omori M., Evarts R.P., Teramoto T., Miller M.J., Hoang T.N., Thorgeirsson S.S. Partial cloning of rat CD34 cDNA and expression during stem cell-dependent liver regeneration in the adult rat. Hepatology 1997, 26:720-727.
61. Ota T., Takamura T., Kurita S., Matsuzawa N., Kita Y., Uno M., Akahori H., Misu H., Sakurai M., Zen Y., Nakanuma Y., Kaneko S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007, 132:282-293.
62. Paternostro C., David E., Novo E., Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J. Gastroenterol. 2010, 16:281-288.
63. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M.H., Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
64. Ramadori G., Saile B. Portal tract fibrogenesis in the liver. Lab. Invest. 2004, 84:153-159.
65. Reeves H.L., Friedman S.L. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front. Biosci. 2002, 7:d808-d826.
66. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
67. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52:59-69.
68. Saeki T., Ichiba M., Tanabe N., Ueki M., Okamoto K., Matsunaga Y., Hosho K., Kanbe T., Tsuchiya H., Kurimasa A., Yamada S., Hirooka Y., Hisatome I., Kishimoto Y., Suou T., Murawaki Y., Kawasaki H., Yodoi J., Shiota G. Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. Liver Int. 2006, 26:157-165.
69. Sahreen S., Khan M.R., Khan R.A. Hepatoprotective effects of methanol extract of Carissa opaca leaves on CCl4-induced damage in rat. BMC Complement. Altern. Med. 2011, 11:48.
70. Schmitt-Graff A., Kruger S., Bochard F., Gabbiani G., Denk H. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am. J. Pathol. 1991, 138:1233-1242.
71. Schmitt-Graff A., Chakroun G., Gabbiani G. Modulation of perisinusoidal cell cytoskeletal features during experimental hepatic fibrosis. Virchows Arch. A Pathol. Anat. Histopathol. 1993, 422:99-107.
72. Serpaggi J., Carnot F., Nalpas B., Canioni D., Guechot J., Lebray P., Vallet-Pichard A., Fontaine H., Bedossa P., Pol S. Direct and indirect evidence for the reversibility of cirrhosis. Hum. Pathol. 2006, 37:1519-1526.
73. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., Kitamura N., Toda K., Kaneko T., Horie Y., Han J.Y., Kato S., Shimoda M., Oike Y., Tomizawa M., Makino S., Ohkura T., Saito H., Kumagai N., Nagata H., Ishii H., Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415-424.
74. Walkey C.J., Yu L., Agellon L.B., Vance D.E. Biochemical and evolutionary significance of phospholipid methylation. J. Biol. Chem. 1998, 273:27043-27046.
75. Wang Y., Ausman L.M., Greenberg A.S., Russell R.M., Wang X.D. Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int. J. Cancer 2009, 124:540-546.
76. Wanless I.R., Nakashima E., Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch. Pathol. Lab. Med. 2000, 124:1599-1607.
77. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
78. Xing X.Y., Zhao Y.L., Kong W.J., Wang J.B., Jia L., Zhang P., Yan D., Zhong Y.W., Li R.S., Xiao X.H. Investigation of the "dose-time-response" relationships of rhubarb on carbon tetrachloride-induced liver injury in rats. J. Ethnopharmacol. 2011, 135:575-581.
79. Zeisel S.H., Da Costa K.A., Franklin P.D., Alexander E.A., Lamont J.T., Sheard N.F., Beiser A. Choline, an essential nutrient for humans. FASEB J. 1991, 5:2093-2098.
80. Zimmermann H., Reichen J., Zimmermann A., Sagesser H., Thenisch B., Hoflin F. Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 1992, 103:579-589.